NCT06892210 Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
| NCT ID | NCT06892210 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Copenhagen Respiratory Research |
| Condition | Chronic Obstructive Pulmonary Disease (COPD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2030-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 2,000 participants in total. It began in 2026-03-10 with a primary completion date of 2030-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days. Participants will randomized to receive treatment with either hydrocortisone or prednisolone.
Eligibility Criteria
Inclusion Criteria: * Age ≥40 years * Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44 Exclusion Criteria: * All diagnoses that would merit treatment with a specific corticosteroid * Pregnant or breastfeeding women * Active tuberculosis or invasive fungal infection
Contact & Investigator
Jens-Ulrik Stæhr Jensen, MD, PHD
STUDY DIRECTOR
COP:RESP
Frequently Asked Questions
Who can join the NCT06892210 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Chronic Obstructive Pulmonary Disease (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06892210 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06892210 currently recruiting?
Yes, NCT06892210 is actively recruiting participants. Contact the research team at jens.ulrik.jensen@regionh.dk for enrollment information.
Where is the NCT06892210 trial being conducted?
This trial is being conducted at Rønne, Denmark, Copenhagen, Denmark, Copenhagen, Denmark, Frederiksberg, Denmark and 10 additional locations.
Who is sponsoring the NCT06892210 clinical trial?
NCT06892210 is sponsored by Copenhagen Respiratory Research. The principal investigator is Jens-Ulrik Stæhr Jensen, MD, PHD at COP:RESP. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.